Abnormal skin findings are identified in over 90% of human immunodeficiency virus (HIV)-infected persons globally. A prospective cohort study of HIV-infected patients with skin complaints commencing antiretroviral therapy (ART) in northern Tanzania was undertaken.
Introduction
Cutaneous symptoms and signs are nearly ubiquitous among human immunodeficiency virus (HIV)-infected patients; 90% will develop at least one cutaneous manifestation associated with HIV infection during the clinical course of their disease. 1 Given the concentration of CD4 + cells within the skin, including CD4 + lymphocytes and Langerhans cells, it is not surprising that the skin plays a critical role in the immunopathogenesis and clinical presentation of HIV infection. 2 The spectrum of associated dermatologic complications includes co-infections caused by bacteria, viruses, dermatophytes and other fungi, mycobacteria, malignancies such as Kaposi's sarcoma, and other miscellaneous conditions. 3 In HIV-infected persons, these dermatologic complications may present with increased severity, an atypical presentation and appearance, and a prolonged course, or may be unresponsive to conventional therapies. 4, 5 In general, many of the skin complications of progressive HIV disease are associated with lower CD4 + cell counts. 5 The spectrum of dermatologic complications may also differ between resource-rich and resource-limited settings (RLSs); for example, papular pruritic eruption (PPE) is a common manifestation in RLSs but not in resource-rich areas, and its occurrence is associated with CD4 + cell counts of <200 cells/ll. 6, 7 Extensive observations have defined a spectrum of anticipated skin findings in each setting. Because many cutaneous complications occur in patients with lower CD4 + cell counts, it is logical to predict that the initiation of antiretroviral therapy (ART) has the potential to improve skin conditions if CD4 + cell counts increase on treatment. Observations in patients beginning ART in resource-rich settings have identified significant improvements in cutaneous findings, in addition to dramatic improvements in HIV-related morbidity and mortality. 8, 9 However, the vast majority of HIV-infected persons who require ART reside within RLSs, where the costs, 12 In addition, ART is frequently initiated simultaneously with co-trimoxazole prophylaxis, which may also cause skin rashes in up to 6% of users. 11, 12 Finally, examples of immune reconstitution syndrome (IRS) have been described in patients beginning ART in RLSs, and the skin may be an important site for localization of an IRS. 13 To address these gaps in knowledge regarding the initiation of ART in RLSs, we prospectively studied a cohort of 100 HIV-infected persons with cutaneous complaints and findings, in whom ART was initiated, in northern Tanzania. 14 All CD4 + cell counts were measured using a Partec cycle flow counter analyzer (Partec GmbH, M€ unster, Germany). Plasma HIV-1 RNA was quantified using the Abbott m2000 RealTime HIV-1 system (Abbott Laboratories, Inc.), which has a lower limit of detection of 75 copies/ml). 15, 16 Digital photographs of affected areas were taken at the time of recruitment and at subsequent follow-up visits, or at any time in the event of new eruptions. Photographs were taken to assess improvement or worsening of the cutaneous condition(s). The Burn Scale Rule of 9s (when applicable) was used to assess the extent of the area affected.
Materials and methods
Burn Scale scores were considered to indicate improvement if the score reached ≤10%, moderate improvement if the score reached >10% and <40%, and no improvement if the score remained at ≥40% from entry to completion of the study.
Subjective improvement indicators were given scores on a Likert scale and classified as indicating that the patient's condition had: improved sufficiently; improved but not sufficiently; remained unchanged; deteriorated slightly; or worsened (Table 1) . Karnofsky scores were also utilized as a performance measure. All measures of responses to treatment are presented for only those subjects continuing ART in an on-treatment analysis.
All subjects began a fixed-dose combination of stavudine 40 mg, lamivudine 150 mg twice daily, and nevirapine 200 mg once daily for the first two weeks, followed by stavudine 40 mg, lamivudine 150 mg, and nevirapine 200 mg twice daily.
Stavudine dosing was adjusted by weight; subjects weighing <60 kg received 30 mg twice daily. Efavirenz was substituted for nevirapine in suspected nevirapine toxicity and zidovudine 
Results
A total of 100 subjects were recruited from October 2006 to June 2007. Women (n = 59, 59%) represented the majority of study participants. The mean age of study subjects was 37 years (range: 16-66 years). The median duration of cutaneous symptoms was 90 days (IQR: 60-180 days). The most common dermatologic findings were PPE (47%), followed by eczema (13%), pruritis (9%), xerosis (7%), tinea infections (5%), herpes zoster (4%), Kaposi's sarcoma (4%), molluscum contagiosum (4%), and plain warts (3%) ( Table 2 ). The median Burn Scale score at baseline was 38% (IQR: 3-80%). All subjects demonstrated clinically advanced HIV disease; 95% of subjects had WHO stage III disease, and 5% had WHO stage IV disease. The median CD4 + cell count at baseline was 120 cells/ll (IQR: 2-202 cells/ll), and 37% of patients had CD4 + cell counts of <100 cells/ll. The median plasma HIV RNA level at baseline was 5.2 log 10 copies/ml (IQR: 2.6-6.6 log 10 copies/ml), and 64% of subjects had RNA levels of >5.0 log 10 copies/ml. A total of 86% of subjects completed six months of follow-up on ART. Reasons for loss to follow-up included abscondment (n = 8), non-adherence to drugs (n = 3), death (n = 2), and adverse drug reactions (n = 1). All 86 of the subjects who completed the study remained on a fixed-dose combination of stavudine, lamivudine, and nevirapine. Of the two patients who died, one had advanced Kaposi's sarcoma with gastrointestinal involvement, and the other developed severe anemia. Two patients had suspected drug reactions involving the skin: one had Stevens-Johnson syndrome attributed to nevirapine, and the second developed a reaction attributed to trimethoprim-sulfamethoxazole.
Cutaneous responses were dramatic in many subjects. The median Burn Scale score decreased from 39% at baseline to 27% and 16% at the first and second followup visits (Fig. 1) . Among the 86 subjects who completed six months of ART, the median Burn Scale score decreased to 7% (IQR: 3-9%). Ten (12%) subjects experienced the complete resolution of dermatologic findings (Burn Scale score: 0%). These patients presented with PPE (n = 3), herpes zoster (n = 2), oral candidiasis (n = 1), molluscum contagiosum (n = 1), tinea (n = 1), hairy leukoplakia (n = 1), and granulomatous candidiasis (n = 1). An example of the complete resolution of dermatologic symptoms in one subject is provided in Figure 2 .
Increases in CD4 + cell counts and responses to ART in plasma HIV RNA levels are shown in Figures 3 and 4 . Among the 92 subjects who completed three months of ART, the mean CD4 + cell count increased from 110 cells/ll at baseline to 474 cells/ll, and 18% and 90% achieved plasma HIV RNA levels of <75 copies/ml and <400 copies/ ml, respectively. At six months, the numbers of participants with plasma HIV RNA of <75 copies/ml and <400 copies/ml increased to 72 (84%) and 85 (99%), respectively (Fig. 4) . Karnofsky status improved from a median baseline score of 70 to a median of 80 following six months of ART. In the 10 subjects who achieved the complete resolution of symptoms, the median change in CD4 + cell count was 440 cells/ll (101 cells/ll at baseline and 541 cells/ll at 6 months; P < 0.001), and the median change in HIV-1 RNA was 5.3 log 10 copies/ml (190,688 at baseline and 26 copies/ml at 6 months; P < 0.001). In addition to the two patients with drug reactions, another three subjects experienced new or worsened dermatologic findings at six months of follow-up. In the three patients with new eruptions, baseline CD4 + cell counts were 4 cells/ll, 135 cells/ll, and 159 cells/ll, and plasma HIV RNA levels were 3.6 log 10 copies/ml, 4.3 log 10 copies/ml, and 2.6 log 10 copies/ml, respectively. Baseline Burn Scale scores were 12, 72, and 56%, respectively, in these patients.
Discussion
This cohort of HIV-infected persons treated with ART in northern Tanzania experienced marked improvements in cutaneous symptoms. The complete resolution of skin abnormalities in 10 (12%) subjects and the decrease in Burn Scale scores from a median of 38% to 7% over six months may highlight the important role of the skin as an indicator of immunologic health. Similar findings have been reported in populations from more wealthy settings 17 and in one previous study in Uganda. 10 In parallel, peripheral blood markers of disease progression, including CD4 + cell counts and plasma HIV RNA levels, improved dramatically. The population under study demonstrated abnormal skin findings at baseline and was mainly recruited from a dermatology clinic. All clinical diagnoses were confirmed by biopsy, and PPE was the most common diagnosis. These findings differ from a previous description of an HIV-infected cohort in Dar es Salaam, in which fungal skin infections represented the most common diagnosis. 18 The reasons for these diagnostic differences are not clear. Our study subjects clearly had progressive HIV disease as documented by WHO Stage III or IV clinical manifestations, low CD4 + cell counts, and elevated plasma HIV 
Percentage of patients

Follow-up visits
Less than 75 copies/ml Less than 400 copies/ml Figure 4 Percentage of subjects with human immunodeficiency virus (HIV) RNA of <75 copies/ml and <400 copies/ml from baseline to 6 months after the initiation of fixed-combination antiretroviral therapy RNA levels. Such late presentations of HIV infection are common in northern Tanzania and more broadly across sub-Saharan Africa. 18, 19 These improvements in skin findings were not specific to any single dermatologic diagnosis and were accompanied by increased Karnofsky status scores. Three patients demonstrated worsened skin disease within two months of the initiation of ART, which indicated IRS; however, these patients had improved by the end of six months of follow-up. The previous study undertaken in Uganda investigated 53 patients with PPE only and found a strong relationship between improvements in skin findings and virologic responses to ART. 10 Our study has extended these findings to a larger population with dermatologic diagnoses beyond that of PPE. All subjects received a fixed-dose combination of stavudine, lamivudine, and nevirapine as their ART regimen in accordance with Tanzanian Ministry of Health guidelines. 19 This ART regimen has demonstrated outstanding CD4 + cell count and plasma HIV RNA responses in other cohorts in RLSs. 18 Our study subjects showed comparable responses in CD4 + cell counts and plasma HIV RNA levels after six months. We were unable to demonstrate a relationship between improvements in skin findings and the magnitude of CD4 + cell count increases or responses in plasma HIV RNA levels below detectable limits. The lack of such a relationship may reflect differences between peripheral blood and cutaneous compartments, a complex balance of immunologic recovery and immune reconstitution inflammatory syndrome in skin, or our small sample size. Adverse drug reactions were uncommon in our population despite the use of trimethoprim-sulfamethoxazole and a nevirapine-containing ART regimen. Only two subjects discontinued their medications over the first six months, the period during which adverse drug reactions are most likely to occur. Two subjects died within the first six months, a relatively low percentage in comparison with those in other cohorts receiving ART in RLSs. 20 In a study performed in 2008 among HIV-1-infected patients in Mozambique, Tanzania, and Malawi, a mortality rate of 7.5% was observed during the first year of ART therapy. 21 The low death rate in the present study may reflect the recruitment of the study cohort from a dermatology clinic rather than a setting in which more severe medical illnesses and complicating opportunistic infections such as tuberculosis would be more common. That we recruited our subjects from a dermatology clinic may have introduced some selection bias into our study, and its results may not be generalizable to all clinical situations. However, cutaneous complaints are widely identified within HIV-infected populations. All subjects were examined by a single observer, whose baseline diagnoses were confirmed by biopsy results. The observer also used repeat photography to assess changes in skin findings over time. Our subjects had low CD4 + cell counts at baseline, and these results may not necessarily be extrapolated to HIV-infected persons with skin complaints and higher CD4 + cell counts who begin ART. Our sample size was relatively small, which may have precluded our ability to identify associations between improvements in skin findings and the magnitude of CD4 + cell count increases and suppression of plasma HIV RNA levels. In summary, the benefits of ART include improvements in skin abnormalities among HIV-infected persons. Healthcare providers and patients with cutaneous problems should consider ART as a promising intervention.
